Edition:
United Kingdom

Amneal Pharmaceuticals Inc (AMRX.N)

AMRX.N on New York Stock Exchange

18.51USD
16 Nov 2018
Change (% chg)

$0.01 (+0.05%)
Prev Close
$18.50
Open
$18.39
Day's High
$18.59
Day's Low
$17.96
Volume
207,637
Avg. Vol
295,060
52-wk High
$24.45
52-wk Low
$13.50

Latest Key Developments (Source: Significant Developments)

Amneal Completes Transition Agreement With Amneal To Begin Selling Levothyroxine
Monday, 12 Nov 2018 

Nov 12 (Reuters) - Amneal Pharmaceuticals Inc ::AMNEAL COMPLETES TRANSITION AGREEMENT WITH LANNETT COMPANY TO BEGIN COMMERCIALIZATION OF LEVOTHYROXINE ON DECEMBER 1ST.AMNEAL PHARMACEUTICALS INC - AGREEMENT ACCELERATES AMNEAL'S TIME TO MARKET WITH HIGH VALUE GENERIC.AMNEAL PHARMACEUTICALS - AMNEAL DOES NOT EXPECT TRANSACTION TO HAVE A MATERIAL IMPACT ON ITS FULL YEAR 2018 RESULTS.  Full Article

Lannett Enters Into Agreement With Amneal Pharmaceuticals For Levothyroxine
Monday, 12 Nov 2018 

Nov 12 (Reuters) - Lannett Company Inc ::LANNETT ENTERS INTO AGREEMENT WITH AMNEAL PHARMACEUTICALS FOR LEVOTHYROXINE.LANNETT COMPANY INC - LANNETT LOCKS IN $50 MILLION OF GROSS PROFIT FOR 16-WEEK PERIOD.LANNETT COMPANY INC - LANNETT WILL RECEIVE AN UPFRONT PAYMENT OF $50 MILLION, OTHER TERMS OF TRANSACTION WERE NOT DISCLOSED.LANNETT COMPANY INC - AGREEMENT ALLOWS LANNETT TO CONTINUE TO RECOGNIZE REVENUE AND EBITDA FOR REMAINDER OF JSP CONTRACT TERM.LANNETT - AMNEAL TO BE CO'S SOLE CUSTOMER FOR LEVOTHYROXINE SODIUM BEGINNING DECEMBER 1, 2018 THROUGH MARCH 23, 2019.  Full Article

Amneal Pharmaceutical's Unit Extends Expiration Dates For Certain Lots Of Generic Adrenaclick Epinephrine Injection
Thursday, 25 Oct 2018 

Oct 25 (Reuters) - Amneal Pharmaceuticals Inc ::EXPIRATION DATES FOR CERTAIN LOTS OF GENERIC ADRENACLICK® EPINEPHRINE INJECTION, USP AUTO-INJECTOR EXTENDED TO 20 MONTHS.AMNEAL PHARMACEUTICALS - CO'S UNIT IMPAX LABORATORIES IS EXTENDING EXPIRATION DATES FOR CERTAIN LOTS OF EPINEPHRINE INJECTION, USP AUTO-INJECTOR.  Full Article

Amneal Announces Approval Of Carmustine For Injection Usp, 100 Mg/Vial - Preparing For Launch
Friday, 19 Oct 2018 

Oct 19 (Reuters) - Amneal Pharmaceuticals Inc ::AMNEAL ANNOUNCES APPROVAL OF CARMUSTINE FOR INJECTION USP, 100 MG/VIAL - PREPARING FOR LAUNCH.AMNEAL PHARMACEUTICALS INC - RECEIVED FDA APPROVAL FOR A GENERIC VERSION OF BICNU.AMNEAL PHARMACEUTICALS INC - PLANNING TO COMMERCIALIZE ITS CARMUSTINE FOR INJECTION IN NOVEMBER 2018.  Full Article

Amneal Announces FDA Approval And Launch Of Generic Chlorpromazine Hydrochloride Tablets Usp And Approval Of Methylergonovine Maleate Tablets Usp
Wednesday, 12 Sep 2018 

Sept 12 (Reuters) - Amneal Pharmaceuticals Inc ::AMNEAL ANNOUNCES FDA APPROVAL AND LAUNCH OF GENERIC CHLORPROMAZINE HYDROCHLORIDE TABLETS USP AND APPROVAL OF METHYLERGONOVINE MALEATE TABLETS USP.  Full Article

Amneal Announces Partnership With American Regent
Friday, 31 Aug 2018 

Aug 31 (Reuters) - Amneal Pharmaceuticals Inc ::AMNEAL ANNOUNCES PARTNERSHIP WITH AMERICAN REGENT ON GENERIC MAKENA® AND PROGRESS ON ITS BUSINESS PLAN WITH ADDITIONAL ANDA APPROVALS AND LAUNCHES.AMNEAL PHARMACEUTICALS INC - WILL DISTRIBUTE A GENERIC VERSION OF MAKENA TO RETAIL CONSORTIUMS.AMNEAL PHARMACEUTICALS INC - RECEIVED APPROVALS FOR TWO NEW TOPICAL PRODUCTS THAT TREAT A VARIETY OF SKIN CONDITIONS.AMNEAL PHARMACEUTICALS INC - WELL-POSITIONED TO ACHIEVE GOAL OF LAUNCHING UP TO 47 NEW PRODUCTS BY END OF YEAR.AMNEAL PHARMACEUTICALS - AMERICAN REGENT WILL MARKET GENERIC VERSION OF MAKENA IN CERTAIN CHANNELS INCLUDING HOSPITAL AND SPECIALTY CHANNELS.AMNEAL PHARMACEUTICALS - ANNOUNCED A 5-YEAR SUPPLY & DISTRIBUTION AGREEMENT WITH AMERICAN REGENT FOR GENERIC ALTERNATIVE TO MAKENA.  Full Article

Amneal Announces Q2 Adjusted Earnings Per Share $0.24
Thursday, 9 Aug 2018 

Aug 9 (Reuters) - Amneal Pharmaceuticals Inc ::AMNEAL ANNOUNCES SOLID SECOND QUARTER 2018 FINANCIAL RESULTS.Q2 REVENUE $413.8 MILLION VERSUS I/B/E/S VIEW $460.8 MILLION.Q2 ADJUSTED EARNINGS PER SHARE $0.24.Q2 GAAP LOSS PER SHARE $0.15.Q2 EARNINGS PER SHARE VIEW $0.22 -- THOMSON REUTERS I/B/E/S.UPDATES 2018 FINANCIAL GUIDANCE.SEES 2018 ADJUSTED EPS $0.90 TO $1.00.AMNEAL PHARMACEUTICALS - SEES 2018 CAPEX $80 MILLION TO $100 MILLION.AMNEAL PHARMACEUTICALS - REVISED 2018 ADJUSTED\EPS GUIDANCE PRIMARILY DUE TO DELAYED TIMING OF DELIVERIES OF EPINEPHRINE AUTO-INJECTOR.  Full Article

Amneal Announces Favorable Ruling Regarding Patent Validity For Zomig Nasal Spray
Friday, 29 Jun 2018 

June 29 (Reuters) - Amneal Pharmaceuticals Inc ::AMNEAL ANNOUNCES FAVORABLE RULING REGARDING PATENT VALIDITY FOR ZOMIG® (ZOLMITRIPTAN) NASAL SPRAY.AMNEAL PHARMA - PANEL OF THREE CIRCUIT JUDGES AFFIRMED RULING THAT LANNETT FAILED TO PROVE U.S. PATENTS PROTECTING ZOMIG NASAL SPRAY WERE INVALID.  Full Article

Amneal Announces Patent Litigation Settlement Agreement With Actavis Concerning Rytary®
Wednesday, 20 Jun 2018 

June 20 (Reuters) - Amneal Pharmaceuticals Inc ::AMNEAL ANNOUNCES PATENT LITIGATION SETTLEMENT AGREEMENT WITH ACTAVIS CONCERNING RYTARY®.AMNEAL PHARMACEUTICALS - UNDER TERMS OF AGREEMENT, AMNEAL WILL GRANT ACTAVIS A LICENSE TO BEGIN SELLING A GENERIC VERSION OF RYTARY ON JULY 31, 2025.AMNEAL PHARMACEUTICALS INC - ADDITIONAL DETAILS REGARDING SETTLEMENT WERE NOT DISCLOSED.AMNEAL PHARMACEUTICALS - LAUNCH OF ACTAVIS'S GENERIC PRODUCT CONTINGENT UPON ACTAVIS GETTING APPROVAL FROM FDA OF ANDA FOR GENERIC VERSION OF RYTARY.  Full Article

Amneal Announces FDA Approval Of Cyclophosphamide For Injection USP, Generic To Cytoxan
Wednesday, 30 May 2018 

May 30 (Reuters) - Amneal Pharmaceuticals Inc ::AMNEAL ANNOUNCES FDA APPROVAL OF CYCLOPHOSPHAMIDE FOR INJECTION USP, GENERIC TO CYTOXAN®.AMNEAL PHARMACEUTICALS INC - COMPANY EXPECTS TO BEGIN SHIPPING PRODUCT SHORTLY.AMNEAL - FDA APPROVAL ON ANDA FOR CYCLOPHOSPHAMIDE FOR INJECTION USP, CO'S AP-RATED THERAPEUTIC EQUIVALENT TO CYTOXAN 500 MG, 1 G, 2 G SINGLE-DOSE VIALS.  Full Article

Israel's Intec Pharma eyes revenue from Parkinson's drug in 2019

TEL AVIV, Nov 7 Israel's Intec Pharma, which is conducting a late stage trial for its long-lasting pill to treat Parkinson's disease, expects to start earning money from the programme sometime in 2019.